Overview

* Myriad Q2 2025 revenue rises 1% yr/yr, beating analyst expectations, per LSEG data

* Adjusted EPS for Q2 2025 beats consensus, per LSEG data

* Co on July 31, entered $200 mln credit facility

* Co raises 2025 revenue guidance

Outlook

* Company raises 2025 revenue guidance to $818 - $828 mln

* Myriad Genetics ( MYGN ) maintains 2025 adjusted EPS guidance of $(0.02) - $0.02

* Myriad Genetics ( MYGN ) aims high single-digit to low double-digit revenue growth over the next five years

Result Drivers

* HEREDITARY CANCER TESTING - Revenue and volume in Oncology grew 9% and 10% yr/yr, driven by MyRisk with RiskScore testing

* GROSS MARGIN IMPROVEMENT - Gross margin increased over 160 basis points yr/yr, benefiting from product mix and laboratory efficiencies

* HEADWINDS EXCLUSION - Excluding $9.5 mln headwinds, revenue increased 5% yr/yr, attributed to UNH coverage discontinuation and EndoPredict divestiture

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $213.10 $201.90

Revenue mln mln (15

Analysts

)

Q2 Beat $0.05 -$0.01

Adjusted (14

EPS Analysts

)

Q2 EPS -$3.57

Q2 Net -$330.50

Income mln

Q2 Gross 71.2%

Margin

Q2 Beat $8.60 -$556,40

Adjusted mln 0 (10

Operatin Analysts

g Income )

Q2 $143.80

Adjusted mln

Operatin

g

Expenses

Q2 $481 mln

Operatin

g

Expenses

Q2 -$329.20

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 9 "hold" and 4 "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

* Wall Street's median 12-month price target for Myriad Genetics Inc ( MYGN ) is $6.00, about 33.7% above its August 4 closing price of $3.98

* The stock recently traded at 51 times the next 12-month earnings vs. a P/E of 52 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)